Image source: Getty Images.
Continue Reading Below
What: Shares of Juno Therapeutics, Inc. (NASDAQ: JUNO)a clinical-stage biopharmaceutical company developing cell-based cancer immunotherapies, fell 24% in July, according to data from S&P Global Market Intelligence. The FDA placed a clinical hold on the company's lead program, bringing all trials with JCAR015 to a standstill. The agency removed the hold much more quickly than it had to, but the stock hasn't been as responsive.
So what:Juno's JCAR015 is a Celgene-partnered program that involves removing a patient's T-cells, and then adding a single gene in a laboratory setting that encourages recognition and destruction of cancerous cells in patients with acute lymphoblastic leukemia (ALL).
Although ALL is the most common form of cancer and leukemia in U.S. children, treatment options are somewhat limited. A majority of children with ALL are cured with standard chemotherapy, but the same approach cures only 20% to 30% of adults.
Juno's JCAR015 fired up oncologists with results from a phase 1 trial that enrolled 51 adult ALL patients with disease progression after standard therapy. During the study, a stunning 41 patients showed a complete response, and among the complete responders, 33 exhibited complete molecular remission. In other words, for about 66% of evaluablepatients who had run out of options, JCAR015 treatment bashed their disease down to levels undetectable with incredibly sensitive diagnostic equipment.
The phase 2 "Rocket" trial with JCAR015 has been designed to support accelerated FDA approval for these patients as soon as next year,but two patients' deaths caused the FDA to halt the trial, nearly derailing the program.
Juno isolated the issue to the addition of a specific chemo drug used to precondition patients before infusion with JCAR015 cells. The FDA could have taken much longer to respond to the change in Juno's procedure, but it lifted the hold just five days after placing it.
Now what:The agency's willingness to expedite its review of Juno's solution to the hold in mere days highlights just how important it views these therapies. Juno is hardly the only company modifying T-cells to seek and destroy various cancers, and its peers' stock prices enjoyed a nice bump.
The high tide, however, failed to lift Juno's boat. Perhaps investors fear removal of the problematic chemotherapy from the preconditioning regimen might not solve the problem. Juno estimates the annual U.S. ALL market size at about $250 million. Success in the resumed phase 2 Rocket trial could send the stock soaring, but another patient death could also lead to its collapse.
A secret billion-dollar stock opportunity The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here.
Cory Renauer has no position in any stocks mentioned. You can follow Cory on Twitter, @TMFang4apples, or connect with him on LinkedIn for more healthcare industry insight. The Motley Fool owns shares of and recommends Celgene. The Motley Fool has the following options: short October 2016 $95 puts on Celgene. The Motley Fool recommends Juno Therapeutics. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.